Needham downgrades Alnylam Pharmaceuticals (NASDAQ: ALNY) from Buy to Hold. The firm said, "Alnylam management reviewed a very productive Q2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE